Cargando…

Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder

Introduction: Response to treatment, according to Clinical Global Impression-Improvement (CGI-I) scale, is an easily interpretable outcome in clinical trials of autism spectrum disorder (ASD). Yet, the CGI-I rating is sometimes reported as a continuous outcome, and converting it to dichotomous would...

Descripción completa

Detalles Bibliográficos
Autores principales: Siafis, Spyridon, Rodolico, Alessandro, Çıray, Oğulcan, Murphy, Declan G., Parellada, Mara, Arango, Celso, Leucht, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305379/
https://www.ncbi.nlm.nih.gov/pubmed/34356141
http://dx.doi.org/10.3390/brainsci11070908
_version_ 1783727560592457728
author Siafis, Spyridon
Rodolico, Alessandro
Çıray, Oğulcan
Murphy, Declan G.
Parellada, Mara
Arango, Celso
Leucht, Stefan
author_facet Siafis, Spyridon
Rodolico, Alessandro
Çıray, Oğulcan
Murphy, Declan G.
Parellada, Mara
Arango, Celso
Leucht, Stefan
author_sort Siafis, Spyridon
collection PubMed
description Introduction: Response to treatment, according to Clinical Global Impression-Improvement (CGI-I) scale, is an easily interpretable outcome in clinical trials of autism spectrum disorder (ASD). Yet, the CGI-I rating is sometimes reported as a continuous outcome, and converting it to dichotomous would allow meta-analysis to incorporate more evidence. Methods: Clinical trials investigating medications for ASD and presenting both dichotomous and continuous CGI-I data were included. The number of patients with at least much improvement (CGI-I ≤ 2) were imputed from the CGI-I scale, assuming an underlying normal distribution of a latent continuous score using a primary threshold θ = 2.5 instead of θ = 2, which is the original cut-off in the CGI-I scale. The original and imputed values were used to calculate responder rates and odds ratios. The performance of the imputation method was investigated with a concordance correlation coefficient (CCC), linear regression, Bland–Altman plots, and subgroup differences of summary estimates obtained from random-effects meta-analysis. Results: Data from 27 studies, 58 arms, and 1428 participants were used. The imputation method using the primary threshold (θ = 2.5) had good performance for the responder rates (CCC = 0.93 95% confidence intervals [0.86, 0.96]; β of linear regression = 1.04 [0.95, 1.13]; bias and limits of agreements = 4.32% [−8.1%, 16.74%]; no subgroup differences χ(2) = 1.24, p-value = 0.266) and odds ratios (CCC = 0.91 [0.86, 0.96]; β = 0.96 [0.78, 1.14]; bias = 0.09 [−0.87, 1.04]; χ(2) = 0.02, p-value = 0.894). The imputation method had poorer performance when the secondary threshold (θ = 2) was used. Discussion: Assuming a normal distribution of the CGI-I scale, the number of responders could be imputed from the mean and standard deviation and used in meta-analysis. Due to the wide limits of agreement of the imputation method, sensitivity analysis excluding studies with imputed values should be performed.
format Online
Article
Text
id pubmed-8305379
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83053792021-07-25 Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder Siafis, Spyridon Rodolico, Alessandro Çıray, Oğulcan Murphy, Declan G. Parellada, Mara Arango, Celso Leucht, Stefan Brain Sci Brief Report Introduction: Response to treatment, according to Clinical Global Impression-Improvement (CGI-I) scale, is an easily interpretable outcome in clinical trials of autism spectrum disorder (ASD). Yet, the CGI-I rating is sometimes reported as a continuous outcome, and converting it to dichotomous would allow meta-analysis to incorporate more evidence. Methods: Clinical trials investigating medications for ASD and presenting both dichotomous and continuous CGI-I data were included. The number of patients with at least much improvement (CGI-I ≤ 2) were imputed from the CGI-I scale, assuming an underlying normal distribution of a latent continuous score using a primary threshold θ = 2.5 instead of θ = 2, which is the original cut-off in the CGI-I scale. The original and imputed values were used to calculate responder rates and odds ratios. The performance of the imputation method was investigated with a concordance correlation coefficient (CCC), linear regression, Bland–Altman plots, and subgroup differences of summary estimates obtained from random-effects meta-analysis. Results: Data from 27 studies, 58 arms, and 1428 participants were used. The imputation method using the primary threshold (θ = 2.5) had good performance for the responder rates (CCC = 0.93 95% confidence intervals [0.86, 0.96]; β of linear regression = 1.04 [0.95, 1.13]; bias and limits of agreements = 4.32% [−8.1%, 16.74%]; no subgroup differences χ(2) = 1.24, p-value = 0.266) and odds ratios (CCC = 0.91 [0.86, 0.96]; β = 0.96 [0.78, 1.14]; bias = 0.09 [−0.87, 1.04]; χ(2) = 0.02, p-value = 0.894). The imputation method had poorer performance when the secondary threshold (θ = 2) was used. Discussion: Assuming a normal distribution of the CGI-I scale, the number of responders could be imputed from the mean and standard deviation and used in meta-analysis. Due to the wide limits of agreement of the imputation method, sensitivity analysis excluding studies with imputed values should be performed. MDPI 2021-07-09 /pmc/articles/PMC8305379/ /pubmed/34356141 http://dx.doi.org/10.3390/brainsci11070908 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Siafis, Spyridon
Rodolico, Alessandro
Çıray, Oğulcan
Murphy, Declan G.
Parellada, Mara
Arango, Celso
Leucht, Stefan
Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title_full Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title_fullStr Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title_full_unstemmed Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title_short Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
title_sort imputing the number of responders from the mean and standard deviation of cgi-improvement in clinical trials investigating medications for autism spectrum disorder
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305379/
https://www.ncbi.nlm.nih.gov/pubmed/34356141
http://dx.doi.org/10.3390/brainsci11070908
work_keys_str_mv AT siafisspyridon imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT rodolicoalessandro imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT cırayogulcan imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT murphydeclang imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT parelladamara imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT arangocelso imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder
AT leuchtstefan imputingthenumberofrespondersfromthemeanandstandarddeviationofcgiimprovementinclinicaltrialsinvestigatingmedicationsforautismspectrumdisorder